ClinicalTrials.gov
ClinicalTrials.gov Menu

Nonopioid Analgesia After Labral Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03825809
Recruitment Status : Recruiting
First Posted : January 31, 2019
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
Toufic R. Jildeh, Henry Ford Health System

Brief Summary:
This is a randomized, single blinded, standard of care controlled clinical trial. This project aims to compare postoperative pain control in patients in two treatment arms of rotator cuff repair: a treatment group given a nonopioid pain control regimen, and a standard of care control group given standard opioid pain control regimen

Condition or disease Intervention/treatment Phase
Narcotic Use Drug: Celecoxib Drug: Hydrocodone-Acetaminophen Drug: Ketorolac Drug: Gabapentin Drug: Acetaminophen Drug: Diazepam Phase 2 Phase 3

Detailed Description:

Study Design: This is a randomized, single blinded, standard of care-controlled clinical trial. All adult patients over eighteen desiring rotator cuff repair will be eligible. Nonnarcotic postoperative pain control regimen described below were chosen based on previous studies in fracture care and joint arthroplasty.

Patients will be consented and recruited. Once participation has been determined and consent obtained, the names of participating patients will be provided to the research pharmacy. Patients will be randomized with a computer-generated table in 2 patient blocks by the research pharmacy. Patients postoperative analgesia will be divided into one of the following 2 treatment arms: 1) A novel nonopioid pain protocol or 2) traditional narcotic pain analgesia

Primary endpoints is reduction in pain as measured by VAS and PROMIS. The endpoints will be collected at each post-operative day using a journal. Moreover, endpoints will be collected at the patient's first post-operative appointment. These appointments are scheduled within one-week of the index procedure.

Statistical Analysis: All continuous data will be analyzed using independent 2-group t tests and reported as means ± standard deviations. Categorical data will be compared between the 2 groups using chi-square tests and reported as counts and percentages. A preliminary test to confirm the quality of variances will be conducted prior to utilizing the t test to confirm the appropriate statistical analysis. Nonparametric equivalents Wilcoxon rank-sum and Fisher exact tests will be used as needed for nonnormal distributions and low variable numbers, respectively. A multivariable regression analysis was performed to assess for potential confounding demographic variables.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Treatment
Official Title: Traditional vs. Nonopioid Analgesia After Labral Surgery
Actual Study Start Date : January 22, 2019
Estimated Primary Completion Date : January 20, 2020
Estimated Study Completion Date : May 20, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Post-Operative Non Opioid Pain Protocol

Patients will be administered a post-operative non-opioid pain protocol consisting of:

Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam

Drug: Celecoxib
Post-Operative Non Opioid Pain Protocol
Other Name: Celebrex

Drug: Ketorolac
Post-Operative Non Opioid Pain Protocol
Other Name: Toradol

Drug: Gabapentin
Post-Operative Non Opioid Pain Protocol
Other Name: Neurontin

Drug: Acetaminophen
Post-Operative Non Opioid Pain Protocol
Other Name: Tylenol

Drug: Diazepam
Post-Operative Non Opioid Pain Protocol
Other Name: Valium

Active Comparator: Post-Operative Traditional Pain Protocol
Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
Drug: Hydrocodone-Acetaminophen
Traditionally used narcotic pain protocol
Other Name: Norco




Primary Outcome Measures :
  1. Pain Levels [ Time Frame: 10 days post-operatively ]
    Patients recorded pain levels 3 times per day using Visual analog scales until study completion. Average daily pain was calculated for each patient. Higher values portend worse control.

  2. Patient-Reported Outcomes Measurement Information System [ Time Frame: 10 days post-operatively ]
    Patient-Reported Outcomes Measurement Information System Physical Interference (PROMIS PI) nightly until study completion. Average PROMIS PI values calculated nightly. A higher score indicates more pain interference.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Eligibility Criteria:

Inclusion Criteria:

  • All adult patients over age 18 and scheduled for a primary or revision labral surgery

Exclusion Criteria:

  • Exclusion criteria will include patients with a medical history of known allergies or intolerance to allergies or intolerance to Celebrex, Tylenol, Neurontin, dexamethasone, tramadol, substantial alcohol or drug abuse, and pregnancy, history of narcotics within 6 months of surgery, renal impairment, peptic ulcer disease, GI bleeding. Secondary exclusion criterion is an intact rotator cuff

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03825809


Contacts
Contact: Toufic R Jildeh, MD 517-230-8511 tjildeh1@hfhs.org

Locations
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Contact: Toufic R Jildeh, MD         
Sponsors and Collaborators
Henry Ford Health System
Investigators
Principal Investigator: Toufic R Jildeh, MD Henry Ford Health System

Responsible Party: Toufic R. Jildeh, Resident Investigator, Henry Ford Health System
ClinicalTrials.gov Identifier: NCT03825809     History of Changes
Other Study ID Numbers: 1231914
First Posted: January 31, 2019    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Per request

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Acetaminophen
Celecoxib
Ketorolac
Ketorolac Tromethamine
Analgesics, Non-Narcotic
Acetaminophen, hydrocodone drug combination
Gabapentin
Hydrocodone
Oxycodone
Diazepam
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents
Anticonvulsants
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants